Market Overview

UPDATE: Deutsche Bank Raines PT to $45 on Medtronic Following Top-Line Beat

Share:
Related MDT
Earnings Scheduled For February 21, 2017
DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) but increased its price target from $43 to $45.

Deutsche Bank noted, "Top line beats, but EPS in line; Maintain Hold. In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42.75 on Wednesday.

Latest Ratings for MDT

DateFirmActionFromTo
May 2017Goldman SachsInitiates Coverage OnNeutral
Jan 2017JP MorganDowngradesOverweightNeutral
Jan 2017Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Pre-Market Outlook Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!